USP17 has also been suggested to represent a potential target for cancer therapy due to its over-expression in a number of tumour tissues [7], its association with recurrence and metastases in non-small cell lung cancer (NSCLC) [50], as well as its necessity for cell cycle progression [7], tumour growth [8] and cell migration [6]. This evidence concerns the gene USP17L2 and non-small cell lung carcinoma.